Eli Lilly’s Phase 3 SEQUOIA trial fails to meet primary endpoint
Category: #health  By Mateen Dalal  Date: 2019-10-18
  • shareshare_icon
  • Twitter
  • Facebook
  • LinkedIn

Eli Lilly’s Phase 3 SEQUOIA trial fails to meet primary endpoint

Metastatic pancreatic cancer (MPC) is one of the most fatal cancers in the world. Pancreatic cancer is slated to be the third leading cause of cancer death in the U.S. and is expected to become the second leading cause of cancer-related death over the coming years. As this is an aggressive cancer, there is a dire need for new treatments to improve clinical outcomes for pancreatic cancer patients.

Eli Lilly and Company has reportedly declared top-line results from its Phase 3 SEQUOIA trial assessing pegilodecakin plus FOLFOX compared to FOLFOX alone in patients who are suffering from metastatic pancreatic cancer whose disease has progressed on one prior gemcitabine-containing regimen. However, the clinical trial failed to meet its primary endpoint of overall survival.

Sources close to the study cite that the most common Grade 3/4 adverse events happening at a higher rate (>5% difference) during SEQUOIA clinical trial were thrombocytopenia, fatigue, neutropenia, and anemia. In-depth safety and efficiency results would be presented at future medical meetings.

Maura Dickler, Vice President, Late Phase Development, Lilly Oncology, said that pancreatic cancer is one most difficult cancer to treat and there had been very few treatment advancements in the later-line metastatic setting.

The company is disappointed by the outcome of this clinical trial, however, is grateful to the patients, researchers, and investigators who took part in it. Dickler added that the company will be focusing on upcoming clinical trial results in lung cancer, taking lessons from these studies and would understand pegilodecakin's novel mechanism of action in cancer immunotherapy in a better way.

Reports cite that, for the next stage of pegilodecakin's clinical trial, Eli Lilly is focusing on conducting studies in NSCLC and assessing biomarkers for the next stage of pegilodecakin's clinical development. The company will also be focusing on other tumor types like renal cell carcinoma where molecules had shown positive activity.

Source Credit - https://investor.lilly.com/news-releases/news-release-details/lilly-announces-phase-3-study-patients-metastatic-pancreatic

  • shareshare_icon
  • Twitter
  • Facebook
  • LinkedIn


About Author

Mateen Dalal     twitter

Mateen Dalal

A qualified electronics and telecommunication engineer, Mateen Dalal embarked on his professional journey working as a quality and test engineer. Harnessing his passion for content creation however, Mateen pens down industry-rich articles for ReportsGO.com and a few o...

Read More..

More News By Mateen Dalal

General Motors to recoup USD 1.9 Bn from LG spent on Bolt EV recall

General Motors to recoup USD 1.9 Bn from LG spent on Bolt EV recall

By Mateen Dalal

GM will recover almost all the costs from the recall of its Bolt EV models. Despite the EV battery manufacturing mishap from LG, the two companies will continue to work together. General Motors (GM) has agreed to recover around USD 1.9 billion f...

Tata Motors records 25% jump in global sales in second quarter of 2021

Tata Motors records 25% jump in global sales in second quarter of 2021

By Mateen Dalal

The automaker’s annual wholesale growth has been around 24%. The company saw a 10% rise in passenger car sales during Q2 2021, as compared to the same period in 2020. Tata Motors Limited reported substantial growth in Q2 2021, with its glo...

Carbon Budgets for corporate business travels to hit airlines: Report

Carbon Budgets for corporate business travels to hit airlines: Report

By Mateen Dalal

With major companies considering ways to reduce carbon emissions from corporate travel, airlines are preparing for a setback in business-class travel, which is an important revenue driver according to industry experts and executives. The airline ind...